How Does Fintepla Work? Mechanism of Action Explained in Plain English

Fintepla (fenfluramine) is a unique antiseizure medication that works differently from most other epilepsy drugs. Understanding how it works can help patients and caregivers make sense of why it's used for specific epilepsy syndromes — and why it requires special safety monitoring.

The Short Answer: How Fintepla Reduces Seizures

The exact mechanisms by which fenfluramine reduces seizures in Dravet syndrome and LGS are not fully understood. However, research points to several key actions involving serotonin — a brain chemical that plays a role in regulating nerve activity — and sigma-1 receptors, which help calm overactive nerve signaling.

What Is Fenfluramine, and How Is It Different from Other AEDs?

Most antiseizure medications (AEDs) work by targeting sodium channels, GABA receptors, or calcium channels to directly suppress abnormal electrical activity in brain neurons. Fintepla takes a different approach — it primarily works through the serotonin system, which gives it a distinct profile compared to most other AEDs used in Dravet syndrome and LGS.

This distinction matters clinically: because Fintepla has a different mechanism than valproate, clobazam, or stiripentol, it can be added on top of these medications and provide additional seizure control even when the other drugs are already being used.

Mechanism 1: Serotonin Releasing Agent

Fenfluramine causes neurons to release stored serotonin — a neurotransmitter (brain chemical messenger) — into the synaptic gap between nerve cells. By increasing serotonin availability in certain brain circuits, fenfluramine activates serotonin receptors that have inhibitory (calming) effects on neuronal activity.

Think of it this way: in epilepsy, groups of neurons fire too rapidly and spread that electrical storm across the brain. Serotonin acts like a "brake" for some of these overactive circuits. By releasing more serotonin, fenfluramine helps strengthen those brakes.

Mechanism 2: Serotonin 5-HT2C and 5-HT2B Receptor Activity

Fenfluramine and its major active metabolite norfenfluramine are agonists at serotonin 5-HT receptors. The 5-HT2C receptor subtype is thought to play a role in regulating seizure thresholds, particularly in the limbic system and cortex — brain regions involved in seizure generation.

The 5-HT2B receptor activity is the reason for Fintepla's boxed warning about valvular heart disease — this receptor subtype is found in cardiac tissue, and its stimulation at high doses has historically been linked to valve abnormalities. At the doses used for epilepsy treatment, this risk appears to be minimal based on clinical data.

Mechanism 3: Sigma-1 Receptor Agonism

Sigma-1 receptors are chaperone proteins located inside cells (at the endoplasmic reticulum membrane) that regulate intracellular calcium signaling and nerve excitability. Fenfluramine acts as an agonist (activator) at sigma-1 receptors.

Sigma-1 receptor activation has been shown to modulate neuronal excitability and may contribute to Fintepla's antiseizure effects by reducing the hyperexcitability that drives seizures in conditions like Dravet syndrome.

Why Fintepla Works in Dravet Syndrome Specifically

Dravet syndrome is most commonly caused by mutations in the SCN1A gene, which encodes a sodium channel (Nav1.1) primarily found in inhibitory interneurons — the brain's "braking cells." When these cells don't work properly, the brain becomes hyperexcitable and prone to seizures.

Fintepla's serotonergic actions appear to partially compensate for the loss of inhibitory interneuron function. By activating serotonin-mediated inhibitory pathways, it helps restore some of the "braking" that the malfunctioning Nav1.1 channels can no longer provide.

This is also why sodium channel blocker medications (lamotrigine, carbamazepine, etc.) are contraindicated in Dravet syndrome — they further suppress the already-impaired sodium channels, worsening the problem. Fintepla bypasses this issue entirely by working through a completely different pathway.

The Pharmacokinetics: How the Body Processes Fintepla

Understanding how Fintepla moves through the body helps explain its dosing schedule and drug interactions:

Absorption: Peak plasma concentration reached in 3-5 hours; ~68-74% bioavailability; food does not affect absorption

Metabolism: Over 75% converted to norfenfluramine (also active) by CYP1A2, CYP2B6, and CYP2D6 enzymes

Half-life: ~20 hours — this is why it's dosed twice daily

Excretion: Over 90% excreted in urine

The CYP enzyme metabolism explains many of Fintepla's drug interactions — drugs that block or induce these enzymes can significantly affect fenfluramine blood levels. Learn more in: Fintepla Drug Interactions: What to Avoid. And if you need help getting Fintepla filled, medfinder can help locate a certified specialty pharmacy.